TNF-α Gene –308 G/A Polymorphism and the Risk of Prostate Cancer: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Mangyuan ¹ , HAN Zhenwei ² , LIU Jiaming ² ,  LIAO Banghua ²

1. West China Medical School, Sichuan University, Chengdu 610041, China;2. Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

LIAO Banghua, Email: ldavid2004@gmail.com

Keywords：

Prostate cancer; Tumor necrosis factor-α; Polymorphism; Meta-analysis

DOI：

10.7507/1672-2531.20120160

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To comprehensively evaluate the association between TNF-α gene −308 G/A polymorphism and the risk of prostate cancer.
Methods 　A meta-analysis was performed to analyze the association between −308 G/A polymorphism and the risk of prostate cancer risk.
Results 　A total of 11 case-control studies (4 919 cases and 5 210 controls) were included in this meta-analysis. The result showed no statistically significant differences in all genotype distribution between prostate cancer cases and controls: dominant model (OR=1.11, 95%CI 0.90 to 1.36, P=0.33), recessive model (OR=0.91, 95%CI 0.70 to 1.18, P=0.47), GA versus GG (OR=1.11, 95%CI 0.90 to 1.37, P=0.33), AA versus GG (OR=0.92, 95%CI 0.71 to 1.20, P=0.55), A versus G (OR=1.07, 95%CI 0.91 to 1.26, P=0.39). In the subgroup analysis by ethnicity, no statistically differences were found between prostate cancer cases and controls.
Conclusion 　This results of meta-analysis suggests that TNF-α gene –308G/A polymorphism may not be a risk factor of prostate cancer. Due to the limited quantity of the includied studies, further studies are needed to validate the above conclusion.

Citation： WANG Mangyuan,HAN Zhenwei,LIU Jiaming,LIAO Banghua. TNF-α Gene –308 G/A Polymorphism and the Risk of Prostate Cancer: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2012, 12(8): 1030-1034. doi: 10.7507/1672-2531.20120160 Copy

1.	American Cancer Society: Cancer facts & ﬁgures. American Cancer Society, Atlanta, 2009.
2.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74–108.
3.	Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate, 1999, 40: 261-268.
4.	Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1 mutation carriers. Lancet, 1994, 343: 692-695.
5.	Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet, 1998, 20: 175-179.
6.	Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC), 1996, 274: 1371-1374.
7.	Tavtigian SV, Simard J, Teng DH, et al. A strong candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 2001, 27: 172-180.
8.	Dufﬁeld-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 2003, 91: 608-612.
9.	Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet, 1999, 64: 776-787.
10.	Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukocyte Biol, 1994, 55: 410.
11.	Danforth KN, Rodriguez C, Hayes RB, et al. TNF Polymorphisms and Prostate Cancer Risk. Prostate, 2008, 68: 400-407.
12.	Lee SO, Chun JY, Nadiminty N, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 67: 764.
13.	Bouraoui Y, Ricote M, García-Tuñón I, et al. Proinﬂammatory cytokines and prostate speciﬁc antigen in hyperplasia and human prostate cancer. Cancer Detect Prev, 2008, 32: 23.
14.	Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med, 1996, 334: 1717.
15.	Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 2008, 29: 573-578.
16.	Sáenz-López P, Carretero R, Cózar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8: 382.
17.	OH BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol, 2000, 163: 1584-1587.
18.	Wu HC, Chang CH, Chen HY, et al. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int, 2004, 73: 41-46.
19.	Moore SC, Leitzmann MF, Albanes D, et al. Adipokine Genes and Prostate Cancer Risk. Int J Cancer, 2009, 124: 869-876.
20.	Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other Immune response- and obesity-related genes with prostate cancer in CLUEII. Prostate, 2009, 69: 874-885.
21.	Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in Tumor Necrosis Factor-A Gene and Prostate Cancer Risk in North Indian Cohort. J Urol, 2009, 186: 2938-2943.
22.	Ge JC, San YX. Studies on the relationship between single nucleotide polymorphisms and susceptibility to Prostate cancer in Chinese population. Zhengzhou University, Zhengzhou, China, 2007.
23.	Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer, 2003, 3: 276-285.
24.	Wingerchuck D, Liu Q, Sobell J, et al. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology, 1997, 49: 626.
25.	Nam RK, Zhang WW, Trachtenberg J, et al. Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clin Cancer Res, 2009, 15: 1787-1793.
26.	Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 1998, 51: 161.

1. American Cancer Society: Cancer facts & ﬁgures. American Cancer Society, Atlanta, 2009.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74–108.
3. Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate, 1999, 40: 261-268.
4. Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1 mutation carriers. Lancet, 1994, 343: 692-695.
5. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet, 1998, 20: 175-179.
6. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC), 1996, 274: 1371-1374.
7. Tavtigian SV, Simard J, Teng DH, et al. A strong candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 2001, 27: 172-180.
8. Dufﬁeld-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 2003, 91: 608-612.
9. Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet, 1999, 64: 776-787.
10. Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukocyte Biol, 1994, 55: 410.
11. Danforth KN, Rodriguez C, Hayes RB, et al. TNF Polymorphisms and Prostate Cancer Risk. Prostate, 2008, 68: 400-407.
12. Lee SO, Chun JY, Nadiminty N, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 67: 764.
13. Bouraoui Y, Ricote M, García-Tuñón I, et al. Proinﬂammatory cytokines and prostate speciﬁc antigen in hyperplasia and human prostate cancer. Cancer Detect Prev, 2008, 32: 23.
14. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med, 1996, 334: 1717.
15. Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 2008, 29: 573-578.
16. Sáenz-López P, Carretero R, Cózar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8: 382.
17. OH BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol, 2000, 163: 1584-1587.
18. Wu HC, Chang CH, Chen HY, et al. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int, 2004, 73: 41-46.
19. Moore SC, Leitzmann MF, Albanes D, et al. Adipokine Genes and Prostate Cancer Risk. Int J Cancer, 2009, 124: 869-876.
20. Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other Immune response- and obesity-related genes with prostate cancer in CLUEII. Prostate, 2009, 69: 874-885.
21. Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in Tumor Necrosis Factor-A Gene and Prostate Cancer Risk in North Indian Cohort. J Urol, 2009, 186: 2938-2943.
22. Ge JC, San YX. Studies on the relationship between single nucleotide polymorphisms and susceptibility to Prostate cancer in Chinese population. Zhengzhou University, Zhengzhou, China, 2007.
23. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer, 2003, 3: 276-285.
24. Wingerchuck D, Liu Q, Sobell J, et al. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology, 1997, 49: 626.
25. Nam RK, Zhang WW, Trachtenberg J, et al. Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clin Cancer Res, 2009, 15: 1787-1793.
26. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 1998, 51: 161.

Previous Article
Evidence-Based Evaluation and Selection of Essential Medicine for Township Health Centre in China: 20. Abortion
Next Article
编前寄语

Chinese Journal of Evidence-Based Medicine

TNF-α Gene –308 G/A Polymorphism and the Risk of Prostate Cancer: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content